Chile has fully vaccinated more than 14 million people over the age of three, out of a population of 19 million, according to the health ministry. Around 11.3 million people have already received a third dose.
The country's campaign started with the Chinese-made Sinovac vaccine, and the expansion of the programme to include fourth doses will use a combination of Sinovac, Pfizer and AstraZeneca jabs.
KUALA LUMPUR, Nov 12 — A real-world study in Chile found that administering Pfizer or AstraZeneca as a third dose for recipients double vaccinated with Sinovac’s Covid-19 vaccine was more effective than a third Sinovac jab.
According to the “Covid-19 vaccine effectiveness assessment in Chile” study released by the Chilean government at a World Health Organization (WHO) consultation on October 25, efficacy in preventing SARS-CoV-2 infection — among individuals double vaccinated with Sinovac — rose to about 93 per cent for a third dose with Pfizer, 91 per cent for AstraZeneca, and 71 per cent for Sinovac.
The 71 per cent efficacy rate for a third Sinovac jab, 14 days after the third shot, was lower than 81 per cent efficacy with two Pfizer-BioNTech doses, 14 days after the second dose. Two Sinovac doses only yielded 50 per cent effectiveness against coronavirus infection, 14 days after the second shot
智利個研究
In preventing intensive care unit (ICU) admission from Covid-19, effectiveness rose to 99 per cent for a third shot with AstraZeneca for those double vaccinated with Sinovac, 93 per cent for a third dose with Pfizer, and 85 per cent for an additional Sinovac jab.
Three Sinovac doses were less effective against ICU admission at 85 per cent than two Pfizer doses (97 per cent) and two AstraZeneca doses (95 per cent).
Strangely, efficacy against hospitalisation and ICU admission declined for a third Sinovac dose compared to two Sinovac doses, from 83 per cent to 81 per cent (hospital admissions) and from 87 per cent to 85 per cent (ICU admissions).
發表於 
返回列表
